CPSE:NOVO B
CPSE:NOVO BPharmaceuticals

Novo Nordisk (CPSE:NOVO B): Revisiting Valuation After a Recent Share Price Decline and Modest Rebound

Novo Nordisk (CPSE:NOVO B) has quietly pushed higher this month, even after a weak past 3 months and a sharp drop year to date, and that divergence is catching investors attention. See our latest analysis for Novo Nordisk. That recent uptick stands in stark contrast to the double digit 90 day share price return slide and a much steeper year to date share price decline. At the same time, the five year total shareholder return still paints a solid long term compounding story, suggesting...
CPSE:ORSTED
CPSE:ORSTEDRenewable Energy

Ørsted (CPSE:ORSTED) Valuation After US Court Overturns Trump-Era Ban on New Wind Projects

A US federal court overturning Donald Trump’s ban on new wind projects has given Ørsted (CPSE:ORSTED) a timely sentiment boost, lifting the stock and refocusing attention on its long term US offshore wind pipeline. See our latest analysis for Ørsted. The latest ruling arrives after a bruising stretch for Ørsted, with a roughly 11 percent 1 month share price return offering a rebound against a steep year to date slide and weak multi year total shareholder returns. This hints that sentiment may...
CPSE:COLO B
CPSE:COLO BMedical Equipment

Is Coloplast’s New Board Leadership And Dividend Policy Altering The Investment Case For Coloplast (CPSE:COLO B)?

At Coloplast’s Annual General Meeting on 4 December 2025, shareholders approved a year-end dividend of DKK 18.00 per DKK 1 share, alongside significant board changes including the election of Niels B. Christiansen and the appointment of Jette Nygaard-Andersen as Chairman and Niels Peter Louis-Hansen as Deputy Chairman. These moves combine refreshed board leadership with a continued dividend payout, signaling ongoing governance renewal alongside confidence in Coloplast’s cash-generation...
CPSE:MAERSK B
CPSE:MAERSK BShipping

Maersk’s DKK 14.4 Billion Buyback Might Change The Case For Investing In A.P. Møller - Mærsk (CPSE:MAERSK B)

A.P. Møller - Mærsk has launched the second phase of its share buy-back program, planning to repurchase up to DKK 7.2 billion of shares between 11 August 2025 and 4 February 2026, bringing total buy-backs under the current program to as much as DKK 14.4 billion and lifting treasury holdings to 6.90% of share capital. This sizeable buy-back signals management’s confidence in capital allocation discipline and amplifies the impact of any future earnings through a shrinking share base. We’ll now...
CPSE:COLO B
CPSE:COLO BMedical Equipment

Coloplast (CPSE:COLO B) Valuation After AGM Board Changes and Newly Approved Year-End Dividend

Coloplast (CPSE:COLO B) packed a lot into its December AGM, with a refreshed boardroom lineup and an approved year end dividend of DKK 18 per share, both giving investors fresh angles to reassess the stock. See our latest analysis for Coloplast. Those boardroom changes and the confirmed dividend land against a weaker backdrop, with a 1 year total shareholder return of roughly negative 31 percent and year to date share price return of about negative 28 percent, suggesting momentum has been...
CPSE:COLO B
CPSE:COLO BMedical Equipment

European Stocks That May Be Trading Below Estimated Value In December 2025

As European markets continue to show resilience, with major indices like the STOXX Europe 600 and Germany’s DAX posting notable gains, investors are keenly observing economic indicators such as inflation trends that suggest stability around the ECB's target. In this environment, identifying stocks that may be undervalued can offer potential opportunities for growth, especially when these companies demonstrate strong fundamentals and a capacity to thrive amid evolving market conditions.
CPSE:RTX
CPSE:RTXCommunications

RTX (CPSE:RTX) Returns to Profitability, Challenging Bearish Narratives Around Sustained Earnings Decline

RTX (CPSE:RTX) just released its full-year 2025 earnings, reporting fourth-quarter revenue of 146.7 million DKK and basic EPS of 0.55 DKK. Looking back, the company has seen revenue fluctuate, with figures ranging from 104.0 million DKK to 165.5 million DKK over the last four quarters, and basic EPS swinging from a loss of -0.90 DKK in Q1 to a high of 0.99 DKK in Q2. With EPS returning to positive territory and net income rising in recent quarters, investors are paying close attention to...
CPSE:DSV
CPSE:DSVLogistics

3 European Stocks That May Be Undervalued By Up To 46.9%

Amid renewed concerns over inflated AI stock valuations and receding expectations for a U.S. interest rate cut, European markets have experienced a downturn, with major indexes such as the STOXX Europe 600 and Germany's DAX seeing notable declines. In this environment of cautious sentiment, identifying undervalued stocks can present opportunities for investors seeking value in solid fundamentals and potential for growth despite broader market challenges.